Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: An open label study

Akkaya, CENGİZ; Sivrioglu, Enver; Akgoz, Semra; Eker, SALİH; Kirli, Selcuk

doi:10.1002/hup.770

Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: An open label study

Copy For Citation

Akkaya C., Sivrioglu E. Y., Akgoz S., Eker S. S., Kirli S.

HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, vol.21, no.5, pp.337-345, 2006 (SCI-Expanded)

Publication Type: Article / Article
Volume: 21 Issue: 5
Publication Date: 2006
Doi Number: 10.1002/hup.770
Journal Name: HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.337-345
Keywords: venlafaxine, reboxetine, depression, anxiety, depression with anxiety features, treatment, DOUBLE-BLIND, FLUOXETINE, RELAPSE, NORADRENALINE, COMORBIDITY, ASSOCIATION, PREDICTORS, MANAGEMENT, DISORDERS, LIFETIME
Bursa Uludag University Affiliated: Yes

Abstract

Objective The aim of this study was to compare the efficacy and tolerability of reboxetine in the treatment of major depressive disorder (MDD) and MDD with anxiety features to venlafaxine XR.